Management of high-risk endometrial cancer: are we there yet?

Endometrial cancer is a diverse disease that includes varying stages and histologies. As a result, the design, completion, and interpretation of large randomised trials comparing adjuvant therapies for this disease, even when well conducted and well analysed, is problematic. This situation is especially true in the study of adjuvant therapy for advanced endometrial cancer, since many patients are diagnosed and treated surgically for early disease, with no indication for adjuvant treatment.